Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium By: Nuvectis Pharma, Inc. via GlobeNewswire December 10, 2024 at 08:00 AM EST Fort Lee, NJ, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium. Event2024 Ladenburg Virtual Oncology Innovators & Investors SymposiumDate12 December 2024Time10 am EST About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action in that it inhibits both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study. Company ContactRon BentsurChairman, Chief Executive Officer and President201-614-3151rbentsur@nuvectis.com Media Relations ContactChristopher M. CalabreseLifeSci AdvisorsTel: 917-680-5608ccalabrese@lifesciadvisors.com Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium By: Nuvectis Pharma, Inc. via GlobeNewswire December 10, 2024 at 08:00 AM EST Fort Lee, NJ, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium. Event2024 Ladenburg Virtual Oncology Innovators & Investors SymposiumDate12 December 2024Time10 am EST About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action in that it inhibits both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study. Company ContactRon BentsurChairman, Chief Executive Officer and President201-614-3151rbentsur@nuvectis.com Media Relations ContactChristopher M. CalabreseLifeSci AdvisorsTel: 917-680-5608ccalabrese@lifesciadvisors.com
Fort Lee, NJ, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium. Event2024 Ladenburg Virtual Oncology Innovators & Investors SymposiumDate12 December 2024Time10 am EST About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action in that it inhibits both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study. Company ContactRon BentsurChairman, Chief Executive Officer and President201-614-3151rbentsur@nuvectis.com Media Relations ContactChristopher M. CalabreseLifeSci AdvisorsTel: 917-680-5608ccalabrese@lifesciadvisors.com
